Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL340978

BENOXAPROFEN
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1

Basic Information

ChEMBL ID CHEMBL340978
Name BENOXAPROFEN
Phase Approved
Structure Type MOL
InChI Key MITFXPHMIHQXPI-UHFFFAOYSA-N

Known Names

Benoxaprofen Benoxaprofene Benoxaprofeno COMPD 90459 COMPOUND 90459 COMPOUND-90459 Coxigon NSC-299582 Opren Oraflex
1
Targets
3
Activities
1
Assay Types
1
PK Parameters
20
Publications
10
Known Names
1
Indications
1
Mechanisms

Molecular Properties

301.7
MW (Da)
4.34
ALogP
3
HBA
1
HBD
63.3
PSA (Ų)
0.78
QED
0
Ro5 Violations
3
Rot. Bonds

Drug Information

Molecule Type Small molecule
First Approval 1982
Availability Withdrawn
Chirality Racemic

Flags

Withdrawn Natural Product
USAN Stem -profen
USAN Year 1976

Extended Properties

Molecular Formula C16H12ClNO3
MW 301.73
Aromatic Rings 3
Heavy Atoms 21
NP-Likeness -1.02

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Arachidonate 12-lipoxygenase inhibitor INHIBITOR Polyunsaturated fatty acid lipoxygenase ALOX12

Indications

Rheumatic Diseases

ATC Classification

M01AE06
benoxaprofen
Level 1: MUSCULO-SKELETAL SYSTEM
Level 2: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

Drug Warnings

Withdrawn
nephrotoxicity
Liver and kidney failure; Gastrointestinal bleeding; Ulcers
Country: Worldwide   Year: 1982
Withdrawn
gastrointestinal toxicity
Serious toxic effects on various organ systems, particularly the gastrointestinal tract, the liver and bone marrow, in addition to previously known effects on the skin, eyes and nails. Subsequent to t...
Country: Worldwide   Year: 1982
Withdrawn
hematological toxicity
Serious toxic effects on various organ systems, particularly the gastrointestinal tract, the liver and bone marrow, in addition to previously known effects on the skin, eyes and nails. Subsequent to t...
Country: Worldwide   Year: 1982
Withdrawn
hepatotoxicity
Liver and kidney failure; Gastrointestinal bleeding; Ulcers
Country: Worldwide   Year: 1982
Withdrawn
carcinogenicity
Liver necrosis; Photosensitivity; Animal carcinogenicity
Country: Worldwide   Year: 1982
Withdrawn
hepatotoxicity
associated with fatal cholestatic jaundice among other serious adverse reactions
Country: Worldwide   Year: 1982
Withdrawn
hepatotoxicity
Serious toxic effects on various organ systems, particularly the gastrointestinal tract, the liver and bone marrow, in addition to previously known effects on the skin, eyes and nails. Subsequent to t...
Country: Worldwide   Year: 1982
Withdrawn
hepatotoxicity
Liver and kidney failure; Gastrointestinal bleeding; Ulcers
Country: Worldwide   Year: 1982
Withdrawn
hepatotoxicity
Liver necrosis; Photosensitivity; Animal carcinogenicity
Country: Worldwide   Year: 1982
Withdrawn
carcinogenicity
Serious toxic effects on various organ systems, particularly the gastrointestinal tract, the liver and bone marrow, in addition to previously known effects on the skin, eyes and nails. Subsequent to t...
Country: Worldwide   Year: 1982

Activity Summary

IC50 3 meas. best 4.0

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
Bile salt export pump
CHEMBL2073674
IC50 4.0 4.0 99100.0 1

Pharmacokinetic Data

Parameter Value Units Species
T1/2 19.0 hr Homo sapiens

Activity Data Samples

Top measurements by pChEMBL value

Target Type Rel. Value Units pChEMBL Assay PubMed
Bile salt export pump IC50 = 99100.0 nM 4.0 Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of S... 21965623

Literature References

PubMed DOI Target Context # Activities
- 10.6019/CHEMBL3885881 Rattus norvegicus 174
6608000 10.1021/jm00369a033 Rattus norvegicus 6
874954 10.1021/jm00216a011 Rattus norvegicus 4
37468498 10.1038/s41467-023-40064-9 Nuclear receptor subfamily 1 group I member 2 3
20014752 10.1021/tx900326k Hepatotoxicity 3
37468498 10.1038/s41467-023-40064-9 Gamma-aminobutyric acid receptor subunit alpha-1 2
37468498 10.1038/s41467-023-40064-9 Progesterone receptor 2
37468498 10.1038/s41467-023-40064-9 Muscarinic acetylcholine receptor M2 2
26948801 10.1016/j.drudis.2016.02.015 Homo sapiens 2
37468498 10.1038/s41467-023-40064-9 Alpha-1A adrenergic receptor 2
21965623 10.1124/dmd.111.040758 Bile salt export pump 2
37468498 10.1038/s41467-023-40064-9 Cannabinoid receptor 1 2
37468498 10.1038/s41467-023-40064-9 Alpha-2A adrenergic receptor 2
37468498 10.1038/s41467-023-40064-9 5-hydroxytryptamine receptor 2A 2
22194678 10.1371/journal.pcbi.1002310 Hepatotoxicity 2
37468498 10.1038/s41467-023-40064-9 5-hydroxytryptamine receptor 2B 2
37468498 10.1038/s41467-023-40064-9 Androgen receptor 2
37468498 10.1038/s41467-023-40064-9 5-hydroxytryptamine receptor 1A 2
- 10.6019/CHEMBL4651402 SARS-CoV-2 2
- 10.6019/CHEMBL3301361 No relevant target 1

Data from ChEMBL 36 via Core Engine